National Science Foundation

Amphix Bio specializes in the development of therapeutic materials aimed at advancing regenerative medicine. The company focuses on creating nanofiber materials that replicate the structure and dynamic properties of human tissues. By integrating biological signals into these materials, Amphix Bio effectively guides cells to initiate regenerative processes. This innovative approach enables the development of therapies for repairing various tissues, including bone, cartilage, muscle, cardiovascular tissues, and nervous system components such as the brain and spinal cord. With expertise in materials science, stem cell biology, biomolecular design, engineering, medical physics, and informatics, Amphix Bio seeks to translate its promising preclinical and clinical trial results into viable treatment options.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

LiteraSeed is a digital health company that has created a clinically validated platform aimed at enhancing communication between patients and healthcare providers. This platform is specifically designed to assist low health literate patient populations, which includes individuals who may face language barriers or have difficulty articulating their health concerns. By facilitating accurate and remote self-reporting of symptoms, LiteraSeed's technology seeks to prevent misdiagnoses, adverse health events, and unnecessary emergency room visits. The company's focus on improving access to care is particularly beneficial for public health providers serving diverse communities, ensuring that disadvantaged patients receive the attention and resources they need for effective healthcare management.

Amplified Sciences LLC is a molecular diagnostics company based in West Lafayette, Indiana, that specializes in the early detection of debilitating diseases, including pancreatic cancer and kidney disease. The company utilizes an ultra-sensitive molecular sensing technology, licensed exclusively from Purdue University, which allows for the detection of disease markers at the single-molecule level. This technology is versatile and disease state agnostic, enabling accurate diagnosis using bodily fluids such as urine and saliva. Amplified Sciences has developed a point-of-care system that combines sensing and assay methods with low-cost biospecimen collection devices, facilitating scalability and accessibility in healthcare settings. Their first application focuses on the early detection of pancreatic cancer, addressing a significant unmet medical need and offering a favorable reimbursement pathway. With a working prototype and published proof of concept data, Amplified Sciences aims to provide healthcare professionals with innovative diagnostics that can operate with a single sample on one instrument.

MelliCell is a biotechnology company focused on addressing chronic diseases through innovative tissue engineering technology that targets fat cells. The company’s platform enables the conversion of human stem cells into mature fat cells, facilitating their accelerated growth to sizes that surpass conventional limits. This technology aims to shrink fat cells and improve metabolic health, making it applicable for treating conditions such as obesity, diabetes, aging, oncology, and inflammation. MelliCell’s experienced team is developing oral small molecules that not only decrease fat mass but also reverse disease hallmarks while preserving lean mass. The efficacy of MelliCell’s technology has been recognized through various awards and partnerships with leading biopharmaceutical firms, highlighting its potential to enhance health outcomes and quality of life for individuals worldwide.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

Astria Biosciences, based in Pittsburgh, specializes in developing innovative diagnostic and therapeutic solutions for cerebrovascular diseases. The company focuses on addressing neurosurgical challenges through molecular biology, advanced analytics, and small-molecule inhibitors, aiming to provide non-surgical alternatives for neurovascular conditions where surgery is currently the primary option.

CenSyn is a healthcare company focused on advancing brain health screening through innovative technology. The company develops a handheld EEG monitoring device that facilitates the expedited screening of conditions such as Alzheimer's, traumatic brain injury, and epilepsy. Their proprietary software allows for long-term brain health management, capturing brain electrical activity in real-time and enabling clinicians to access EEG data wirelessly from any location. This technological approach not only aids in the rapid diagnosis of various brain health issues but also supports immediate treatment, ultimately aiming to reduce inpatient costs. By making brain health screening more accessible, CenSyn seeks to improve outcomes for diverse patient populations.

CerFlux specializes in personalized medicine technology designed to match cancer treatments with individual tumors. The company's tests aim to identify effective and efficient cancer treatments tailored to each patient, helping to separate optimal from ineffective options. By doing so, CerFlux seeks to improve outcomes and quality of life for patients while reducing the time, pain, and cost associated with cancer treatment.

Metfora is a company focused on developing advanced blood test services aimed at the early detection of chronic lung and heart disorders, as well as various cancers. By utilizing artificial intelligence, Metfora analyzes patterns in circulating metabolites within patients' blood samples. This innovative approach enables the identification of diseases at their initial stages, allowing healthcare professionals to diagnose serious conditions even when symptoms are minimal. The company's commitment to enhancing early diagnostic capabilities positions it as a key player in the field of medical testing, ultimately aiming to improve patient outcomes through timely intervention.

BLOCKsyncop is a company focused on developing innovative clinical monitoring devices aimed at enhancing anesthesiology practices. Its primary product is a non-invasive, real-time tool designed to objectively measure and quantify the effectiveness of neural blocks for pain management. This technology assists anesthesiologists in reducing the occurrence of failed neural blocks, minimizing anesthetic toxicity, and optimizing the analgesic requirements for patients. By providing precise data, BLOCKsyncop aims to improve patient outcomes in pain management and support healthcare professionals in delivering safer and more effective anesthesia care.

CoraVie Medical is an early-stage medical device startup focused on improving blood pressure management for high-risk patients with uncontrolled hypertension. The company's innovative product is an implantable device that continuously monitors blood pressure, providing early warnings of dangerous levels that could lead to organ damage such as kidney failure or heart issues. This data is transmitted remotely via a cloud-based platform, enabling timely clinical interventions and potentially preventing hypertension crises.

CPR Therapeutics is a medical device company focused on developing an advanced automated cardiopulmonary resuscitation (CPR) system. The company's innovative technology integrates multiple technological advancements into a single system designed for easy application under emergency conditions. This multimodal CPR system enhances blood flow and the efficacy of electrical countershock, capabilities that are beyond human performance. By combining chest compressions with artificial ventilation, the system aims to preserve brain function and restore spontaneous circulation and breathing in cardiac arrest patients, thereby improving survival rates significantly.

Claria Medical is a pre-commercial medical device start-up focused on addressing unmet needs in women's healthcare, particularly in gynecologic surgery. The company specializes in the development of minimally invasive surgical tools designed to enhance procedures such as hysterectomy and myomectomy. Claria Medical has achieved early recognition for its innovative approach, receiving a "Safer Technologies Designation" from the U.S. Food and Drug Administration. Additionally, the company has secured funding through private financing, as well as prestigious grants from the National Science Foundation and the National Institutes of Health, to support the advancement of its medical devices aimed at improving surgical outcomes for women.

OncoSTING LLC, established in 2018 and headquartered in Baltimore, Maryland, specializes in developing innovative therapies for bladder cancer. The company's primary focus is on creating a novel treatment that combines the potency of standard Bacillus Calmette-Guérin (BCG) immunotherapy with long-lived delivery of potent Stimulator of Interferon Genes (STING) agonists. This approach aims to enhance therapeutic efficacy while reducing adverse events associated with traditional BCG treatments, ultimately working towards curing bladder cancer.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Oxalo Therapeutics is a biopharmaceutical company focused on developing innovative drug therapies for rare kidney diseases and the prevention of recurrent kidney stones. The company's primary target is primary hyperoxaluria and other oxalate-related conditions. Leveraging expertise in the microbiome and translational research, Oxalo Therapeutics has developed a novel approach that mimics natural mechanisms for safely removing oxalate from the body. This method aims to effectively prevent the formation of kidney stones and address renal diseases associated with elevated oxalate levels, thereby improving patient outcomes and quality of life.

EzraBio is a biotechnology company focused on enhancing ribosome profiling for researchers across various biological samples. The company specializes in RNA adenylation technology, which facilitates efficient and rapid cDNA library construction. By offering streamlined services that encompass sample preparation and deep sequencing, EzraBio aims to simplify the ribosome profiling process. This innovative approach allows medical professionals to uncover hidden coding potential, analyze translational responses, identify tumor-associated antigens, and advance mRNA therapeutics. Through its cutting-edge solutions, EzraBio supports researchers in their quest to deepen understanding of complex biological mechanisms.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the underlying causes of these conditions, particularly immune evasion and drug resistance. Its primary focus is on creating market-disruptive biologics for recurrent and drug-resistant cancers, specifically addressing the needs of patients with recurrent metastatic breast cancer. By concentrating on these critical areas, Creative BioTherapeutics seeks to enable medical professionals to provide effective treatments for both adult and childhood cancers, potentially leading to tumor regression and improved patient outcomes.

Simmbion is a biotechnology company that develops innovative therapies using symbionts, which are microorganisms that live harmoniously within the human body. Their core business involves creating therapeutic agents within the body itself, eliminating the need for complex manufacturing processes, frequent injections or infusions, temperature-sensitive storage, and high associated costs. This patient-centric approach aims to enhance healthcare outcomes while minimizing risks of infection or immune rejection. Simmbion's technology is adaptable across various health applications, universally compatible with human immunity, long-lasting (a single injection can last up to 12 weeks), and resistant to supply chain disruptions, making it an affordable and equitable solution for diverse patient populations worldwide.

Iaso Therapeutics is a therapeutics company established in 2018 and located in East Lansing, Michigan. The company specializes in the development of vaccines aimed at improving human health and addressing infectious diseases. Its platform is designed to create vaccines targeting various deadly infections, including smallpox, yellow fever, and tetanus. By focusing on innovative vaccine technologies, Iaso Therapeutics seeks to equip healthcare professionals with effective tools to combat diseases and enhance overall public health.

Lura Health is a pioneering company that has developed a non-invasive continuous health monitoring platform utilizing saliva as a diagnostic fluid. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company focuses on chronic disease management, targeting conditions such as heart disease, chronic kidney disease, diabetes, and tooth decay. Lura Health's innovative sensors are designed to be integrated into patient-friendly orthodontic devices, including removable retainers and fixed brackets. These sensors continuously monitor oral acidity and other analytes in saliva, automatically transmitting valuable health data to a mobile application. This approach empowers users to track key diagnostic metrics within their oral environment, facilitating improved personal health management and potentially enhancing clinical outcomes.

Amphix Bio specializes in the development of therapeutic materials aimed at advancing regenerative medicine. The company focuses on creating nanofiber materials that replicate the structure and dynamic properties of human tissues. By integrating biological signals into these materials, Amphix Bio effectively guides cells to initiate regenerative processes. This innovative approach enables the development of therapies for repairing various tissues, including bone, cartilage, muscle, cardiovascular tissues, and nervous system components such as the brain and spinal cord. With expertise in materials science, stem cell biology, biomolecular design, engineering, medical physics, and informatics, Amphix Bio seeks to translate its promising preclinical and clinical trial results into viable treatment options.

Visicell Medical is a company focused on advancing stem cell-based therapies by developing safe and biodegradable tracking tools for stem cells. These innovative tools allow for real-time monitoring of injected stem cells in patients, facilitating both clinical and pre-clinical applications. Additionally, Visicell Medical specializes in medical imaging technology that enhances the early detection and diagnosis of diseases. The company offers specialized image capture systems and analysis tools that provide high-resolution, three-dimensional views of tissues or cells, enabling medical professionals to detect abnormalities with greater accuracy. This capability supports earlier interventions and improved treatment outcomes, potentially lowering overall healthcare costs.

Cytocybernetics is a biotechnology company that specializes in cellular electrophysiology. The company has developed the Cybercyte, a powerful and user-friendly plug-and-play dynamic clamp system designed to facilitate advanced research. In addition to its innovative products, Cytocybernetics offers a comprehensive range of contract research organization (CRO) services. These services include FDA-mandated drug safety screening, as well as custom electrophysiology, modeling, and analysis tailored to meet the specific needs of its clients. By providing these solutions, Cytocybernetics supports a variety of cellular research and product development initiatives.

Nostopharma is a healthcare company focused on developing treatments for pathologic bone growth aimed at preventing rare bone diseases. Its innovative approach includes a nanoparticle drug delivery system designed to address complications arising from soft tissue trauma. The company's therapies support patients in regenerating bone after surgeries, burns, injuries, and other traumatic events, ultimately enhancing clinical outcomes for those suffering from post-traumatic conditions. By reducing complications associated with surgical procedures, Nostopharma also aims to alleviate the societal costs linked to rehabilitation for surgery patients.

InvVax, Inc. is a vaccine development company based in Los Angeles, California, founded in 2012. The company specializes in creating and commercializing innovative vaccines, with a primary focus on a universal influenza vaccine that aims to prevent pandemics. InvVax utilizes a proprietary platform that targets virus mutations by analyzing the invariance of flu proteins, enabling physicians to deliver effective prevention against viral diseases. In addition to its work on influenza, the company is also exploring vaccine candidates for HIV, Hepatitis B, and Hepatitis C, further broadening its impact on public health.

Isolere Bio, established in 2018, is a healthcare company specializing in biotherapeutic purification. Its core business involves simplifying and optimizing the manufacturing process of monoclonal antibodies and Adeno-Associated Viruses (AAVs) using Tangential Flow Filtration (TFF) technology. This streamlined approach aims to enhance global access to these vital drugs and research tools, while facilitating a seamless transition from laboratory-scale production to industrial-level output.

Oncurie is a biotechnology company focused on developing targeted radionuclide therapy aimed at treating metastatic cancer. Utilizing innovative molecular radionuclide technology, Oncurie seeks to deliver radionuclides selectively to metastatic tissues, thereby enhancing treatment efficacy and improving patient outcomes. The company's goal is to provide healthcare providers with advanced therapeutic options that may lead to a cure for various forms of metastatic cancer, including breast cancer. Through its research and development efforts, Oncurie is committed to transforming cancer treatment and addressing unmet medical needs in oncology.

MBF Therapeutics, Inc. is a veterinary oncology company based in Ambler, Pennsylvania, focused on developing and commercializing innovative therapies for cancer treatment in dogs and cats. The company specializes in targeted immunotherapies and small molecule drugs that effectively disrupt tumor cell metabolism while preserving healthy cells and organs. Its product portfolio includes MBFT-101, a combination therapy for sarcomas and lymphoma, featuring a proprietary polyamine transport inhibitor and a potent inhibitor of ornithine decarboxylase, as well as MBFT-102, an immunotherapy based on the tumor suppressor/cytokine mda-7/IL24, which has shown promise in human cancers. Additionally, MBF Therapeutics employs a proprietary DNA vaccine platform and delivery system to develop immunotherapeutic vaccines aimed at enhancing protective immunity against infectious diseases in companion animals and livestock. The company maintains a strategic partnership with the Lankenau Institute for Medical Research to further advance its research and development initiatives.

Vulcan Biologics, established in 2019 and based in Irvine, California, specializes in biotechnology solutions for modulating microbiomes. Its core platform employs bacteriophages, which selectively target and alter specific gut bacteria without affecting the human host, aiming to achieve stable and persistent changes in the microbiome. This approach is primarily focused on treating gluten-related disorders, including gluten sensitivity and celiac disease.

Astek Diagnostics is a healthcare company that develops precision diagnostic technology aimed at improving the diagnosis and treatment of bacterial infections. The company has created a platform that assists physicians in prescribing the correct antibiotics for patients suffering from bacterial sepsis within one hour. Utilizing a single-use cartridge, Astek Diagnostics' device identifies bacterial infections in urine by measuring the oxygen consumption of bacterial species, significantly reducing the turnaround time for results. This innovative approach not only facilitates timely treatment but also helps combat antibiotic resistance through effective susceptibility testing.

BioSapien is a pre-clinical biotechnology company focused on developing innovative biodegradable implantable products for targeted drug delivery in oncology. The company is creating a 3D-printed drug delivery platform known as MediChip, which is designed to administer active pharmaceutical ingredients in a localized and sustained manner. This technology aims to reduce systemic side effects associated with high-dose systemic therapies by delivering drugs directly to cancerous tumor sites. Currently, BioSapien's applications are being explored for pancreatic and lung cancers, with plans to expand its pipeline to include other cancer types such as colorectal, breast, and stomach cancers. The biodegradable mesh used in their products allows for effective treatment while improving patients' quality of care and life.

Clairways is a developer of innovative wearable technology focused on lung health monitoring, specifically designed for use in pharmaceutical clinical trials. The company's digital lung function monitor captures essential respiratory metrics for individuals suffering from chronic respiratory diseases such as asthma, COPD, and cystic fibrosis. This device is equipped with acoustic sensors and machine learning technology, allowing it to detect and characterize various respiratory metrics. By presenting this data in a clear and understandable format, Clairways enables healthcare professionals to monitor patients' respiratory conditions effectively and gain a comprehensive, long-term perspective on their respiratory health.

Felix Biotechnology, Inc. is a San Francisco-based company founded in 2019 that specializes in developing biotherapeutics to combat microbial challenges in human health. The company focuses on creating treatments for antibiotic-resistant strains of bacteria and fungi, aiming to address the urgent need for effective management of infectious diseases. By accelerating the deployment of novel biotherapeutics, Felix Biotechnology seeks to provide healthcare professionals with precise and effective tools to tackle these pressing health issues.

Biochip Labs is a company based in Cleveland, Ohio, founded in 2019. It specializes in providing laboratory testing services focused on blood disorders, particularly sickle cell disease and thalassemia. The company offers a range of proprietary microfluidic biomarker assays, including tests for blood cell adhesion, red blood cell deformability, whole blood rheology, and endothelialized microfluidics. These assays are designed to evaluate the effectiveness of emerging targeted and curative therapies, allowing clinicians to monitor patients' responses to treatment accurately.

xMD Diagnostics, based in Annapolis, Maryland, specializes in the biotechnology sector, focusing on molecular diagnostics tools that enhance research and clinical laboratory practices. Formerly known as Bay Resources Development Group, the company employs advanced high-throughput microdissection technology to aid in cancer diagnosis. Its innovative tools enable the isolation and enrichment of specific cells from biopsy and other specimen samples, facilitating downstream applications such as polymerase chain reaction (PCR), genomic and proteomic analyses, next-generation sequencing (NGS), and various molecular testing methods. This technology supports pathologists, oncologists, and other medical professionals in diagnosing, monitoring, and treating patients with cancer and serious genetic diseases.

Niche Biomedical is a platform and therapy development firm that specializes in innovative treatments for chronic injuries and disorders that have not responded to conventional pharmacological methods. The company has developed the ExaStim, a non-invasive neuromodulation system designated as an FDA Breakthrough Device, aimed at treating spinal cord injuries. Additionally, Niche Biomedical is working on a gastrointestinal therapeutic device designed to alleviate postoperative ileus and restore gastrointestinal motility. This device leverages bioelectronic medicine to address diseases and injuries that are resistant to pharmaceutical therapies. The firm is also capable of creating miniaturized implantable devices with advanced functionalities, allowing for diverse electrode configurations to enhance treatment options through neuromodulation.

SpineX Inc. is a clinical-stage medical device company focused on developing non-invasive neuromodulation technologies for individuals with neurological conditions. The company aims to address unmet medical needs by creating devices that support recovery and restoration of functions such as bladder, bowel, respiration, sexual, and sensorimotor capabilities. Their flagship device, the SCiP, is designed to treat neurological dysfunctions, particularly related to conditions like cerebral palsy. SpineX's commitment to advancing neuromodulation therapy stems from its goal to enhance the quality of life for patients recovering from strokes, spinal cord injuries, multiple sclerosis, traumatic brain injuries, and other related ailments.

Kodikaz Therapeutic Solutions is a biotechnology company focused on developing targeted cancer therapies that aim to provide durable cures while minimizing side effects associated with traditional treatments. The company has created the Zip-Code™ Technology platform, a pioneering cell-specific delivery system designed for a wide range of gene therapy applications. This innovative platform leverages endogenous human mechanisms to avoid the complications associated with viral delivery methods. By translating previously unknown cell-recognition and genomic integration mechanisms, Kodikaz enables the development of cell-specific gene transfer technologies tailored for various cancers, including pancreatic, myeloma, and colorectal. Through its research and development efforts, the company generates both in-vitro and in-vivo data to support the advancement of curative therapies in oncology.

Frontier Bio Corporation is a biotechnology company based in Oakland, California, focused on developing and manufacturing advanced bioprinting technologies. Founded in 2018, the company specializes in creating lab-grown human tissues as an ethical alternative to animal studies. Its flagship product, the FLUX-1, is a 3D bioprinter that integrates conventional bioprinting methods with electro-hydrodynamic printing capabilities. This device enables the bioprinting of complex tissues such as skin, cartilage, and bone, and allows for applications in drug toxicity testing, tissue implants, drug screening, disease modeling, and prosthetics. By providing a means to produce human tissues with complete cell survivability, Frontier Bio aims to enhance the healthcare industry's ability to replace animal testing and address the organ transplant waitlist.

TheraCea Pharma is a biotechnology company based in Tucson, Arizona, that focuses on developing precision medicine for individuals with neurological disorders. As a spin-off from the University of Arizona, the company has developed and licensed advanced radiochemistry technology that facilitates high-efficiency and rapid fluorine-18 radiolabeling of biomolecules for both clinical and research applications. TheraCea Pharma's innovative approach includes creating treatments that address dyskinesia, particularly effects related to L-dopa, a common medication for Parkinson's disease. By providing new diagnostic agents, the company aims to enhance the detection of cancer and improve therapeutic outcomes for patients suffering from neurological conditions.

ZelosDx is a company focused on developing neurodiagnostic technologies, specifically blood testing products aimed at advancing research in brain health and disease. It offers proprietary technology that allows research collaborators to license and adapt blood testing kits and automated laboratory equipment. Additionally, the company provides pharmaceutical partners with biomarker technology essential for drug discovery tools. By delivering critical data for diagnosis, monitoring, and assessing therapeutic responses, ZelosDx supports researchers and pharmaceutical companies in making significant breakthroughs in understanding and treating brain-related conditions.

Ancilia Biosciences is a biotechnology company focused on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components of the gut microbiome. By concentrating on enhancing healthy gut bacteria and their predatory phages, Ancilia develops therapeutic strains that can effectively combat chronic diseases in the fields of immunology and oncology. Additionally, the company is pioneering a new class of live biotherapeutics that allow for the precise targeting of phages or viruses known to induce lysis, thereby advancing treatment options in microbiome-related health conditions.

LumenAstra, established in 2020 and headquartered in Longmont, Colorado, specializes in the development of non-invasive, wearable deep-tissue temperature sensors. These devices are designed to accurately measure internal temperatures from external locations, serving diverse applications such as cancer hyperthermia therapy, hypothermia for aortic dissection repair, brain temperature monitoring for newborns, and heat stress monitoring in high-risk environments like military operations or hazardous workplaces. The company's innovative sensor technology enables medical professionals to better protect patients from potential harm caused by extreme temperatures.

Paramita Therapeutics is a San Diego-based biotech company established in 2018, dedicated to developing innovative therapeutics for cancer and infectious diseases. The firm specializes in the rapid transition of new therapeutics to clinical applications through a patented multi-functional chemical platform. This approach allows Paramita Therapeutics to create multivalent drug conjugates derived from well-known and approved molecules, ensuring a solid safety and toxicology profile. By leveraging its expertise, the company aims to provide patients with access to effective cancer treatments and dual-function therapeutic and vaccine products.

ALSUS MEDICAL offers treatment for urinary stream problems that may be weak or stop and start. In some cases, it can lead to infection, bladder stones, and reduced kidney function. They offer treatments that include medication that relaxes or shrinks the prostate, surgery, and minimally invasive surgery.

LiteraSeed is a digital health company that has created a clinically validated platform aimed at enhancing communication between patients and healthcare providers. This platform is specifically designed to assist low health literate patient populations, which includes individuals who may face language barriers or have difficulty articulating their health concerns. By facilitating accurate and remote self-reporting of symptoms, LiteraSeed's technology seeks to prevent misdiagnoses, adverse health events, and unnecessary emergency room visits. The company's focus on improving access to care is particularly beneficial for public health providers serving diverse communities, ensuring that disadvantaged patients receive the attention and resources they need for effective healthcare management.

Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative therapies for distressed neurological conditions and associated symptoms, including pruritus resulting from liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which enhances drug delivery by avoiding first-pass metabolism and significantly reducing glucuronide metabolites excreted by the kidneys. This technology aims to provide effective relief from various conditions, such as insomnia, anxiety, depression, and skin excoriation, thus offering improved efficacy and safety for patients. With a strong management team, an experienced advisory board, and a dedicated group of scientists and clinicians, Avior Bio is well-positioned to advance its mission of delivering high-value therapeutic solutions.

Verantos is the market leader in high-validity real-world evidence for life sciences. By incorporating robust clinical narrative data, artificial intelligence technology, and measured validity, Verantos is the first company to generate research-grade evidence at scale across all therapeutic areas. The Verantos Evidence Platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for market access, HEOR, medical affairs, and regulatory use.

Gate Scientific makes products that enable great research and improve healthcare decisions by bringing to market intuitive solutions that simplify complex problems. By bringing to market intuitive solutions that simplify complex problems, they allow for the latest technologies to benefit more people.

SpheroFill is a drug delivery platform that specializes in creating innovative injectable tissue fillers, specifically designed to address age-related atrophy in the larynx. Utilizing a unique combination of solid, hollow, and porous-wall hollow glass microspheres along with biocompatible and bioactive matrices, SpheroFill enhances drug delivery for healthcare professionals. Its technology enables improved patient compliance by reducing dosing frequency and allows for oral formulations that current technologies cannot achieve. By focusing on the protection, delivery, and controlled release of active pharmaceutical ingredients, SpheroFill represents a significant advancement in the field of drug administration.

Precision Theranostics is a biotechnology company established in 2019 and headquartered in Baltimore, Maryland. The company focuses on developing prognosis-based intervention strategies aimed at the early detection and treatment of fatal diseases. Its innovative platform estimates disease progression for respiratory diseases and age-related disorders, facilitating the creation of novel diagnostics, therapeutics, and prognosis-based therapies. By enabling healthcare professionals to provide timely diagnoses and interventions, Precision Theranostics seeks to enhance patient survival rates and prevent the development of chronic and life-threatening conditions.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Amberstone Biosciences is a biotechnology company focused on discovering novel immunotherapies aimed at addressing challenging medical targets that traditional methods struggle to tackle. The company utilizes its proprietary microfluidics-powered AmberFlow drug-discovery platform, which allows for the analysis of single-cell function within a customizable microenvironment. This innovative approach, combined with the expertise of its team in immuno-oncology and single-cell assay biology, positions Amberstone to develop transformative therapeutic antibodies that cater to patients with unmet medical needs. Through creative partnerships and advanced technologies, Amberstone Biosciences seeks to overcome conventional limitations in therapeutic development, ultimately enhancing patient care and outcomes.

Cobio Diagnostics is a biotechnology company founded in 2016 and located in Golden, Colorado. The company specializes in developing diagnostics for bacterial identification and phenotypic antibiotic resistance testing. Utilizing a phage-based immunoassay, Cobio Diagnostics' technology allows for the rapid identification of specific bacterial species and the assessment of antibiotic susceptibility, achieving results in under five hours. This innovative approach provides a faster and more targeted alternative to conventional diagnostic methods, enabling healthcare providers to make prompt and informed decisions regarding antibiotic treatments for patients with bacterial infections.

BondTrue LLC is a medical device company focused on enhancing surgical precision through automation. The company has developed a patented device that automates the processes of surgical incisions and closures, enabling surgeons to achieve clean and consistent results while improving the accuracy of surgical procedures. This innovative technology allows for the rapid approximation and repair of surgical wounds, facilitating a more efficient workflow in the operating room. Recently, BondTrue received a Phase II award from the Maryland Industrial Partnerships program, which will support further development and research on their device. Through this funding, BondTrue aims to refine its prototype designs for subsequent research and testing, positioning itself as a key player in the advancement of surgical technologies.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

GRI Bio, Inc. is a clinical-stage biotechnology company based in La Jolla, California, focused on developing innovative therapies for liver disease and autoimmune disorders. The company specializes in harnessing Natural Killer T (NKT) cell-based therapies to address dysregulated immune responses associated with inflammatory and fibrotic diseases. One of its primary product candidates, GRI-0621, is an oral small molecule that inhibits type 1 NKT cells, aiming to restore immune system balance in patients with liver conditions. Additionally, GRI Bio is advancing GRI-0803, an oral agonist targeting type 2 NKT cells. Established in 2009, GRI Bio is committed to discovering and commercializing effective treatments for serious health challenges linked to immune system dysfunction.

iReprogram is a cell regeneration laboratory based in Ann Arbor, Michigan, established in 2017. The company focuses on advancing personalized medicine through innovative cell reprogramming technology. By utilizing a high-fidelity prototype computational tool, iReprogram generates transcription factor recipes that facilitate cellular trans-differentiation, particularly for cancer treatment. This technology aims to enhance the effectiveness of cancer therapies, ultimately allowing patients to benefit from more tailored and effective treatment options.

Progenitor MDX is a biotechnology company focused on developing advanced cellular immunotherapy technologies and innovative solutions for managing COVID-19 infections. The company offers a comprehensive approach that includes testing and actionable infection management plans, aimed at providing reassurance to communities. In addition to its COVID-19 management solutions, Progenitor MDX specializes in cellular reprogramming, utilizing a streamlined method that incorporates all Yamanaka factors into a single vector. This technology enables the creation of allogeneic off-the-shelf CAR constructs from various cell sources, facilitating the efficient insertion of multiple genetic elements. By enhancing the industrial workflows for producing engineered cell therapies, Progenitor MDX plays a critical role in advancing immune-oncology and the development of new therapeutic options.

Akanocure Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative anti-cancer therapies aimed at treating various forms of cancer, particularly those that have metastasized. Recognizing that metastasis is responsible for the majority of cancer-related deaths, Akanocure focuses on creating novel small molecules that can block metastatic processes. The company's approach emphasizes the synthesis and development of bio-targeted chemotherapeutic agents derived from natural resources, which not only target cancer cells more effectively but also address the side effects associated with conventional chemotherapy. By leveraging the expertise of its team throughout the drug discovery and development process, Akanocure aims to enhance treatment outcomes and improve the quality of life for cancer patients.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

BiomeSense, Inc. is a Chicago-based company founded in 2018 that focuses on developing a comprehensive platform for microbiome data collection and analysis. Its primary innovation is the GutLab, a "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology is integrated with the MetaBiome time-series analytics platform, offering a seamless end-to-end solution that enables real-time tracking of microbiome changes and their correlation with clinical outcomes. By generating and analyzing extensive longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, providing healthcare professionals with a high-resolution microbiome database. This resource supports the development of advanced microbiome-based therapeutics and consumer products, ultimately enhancing precision medicine and improving health outcomes.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the underlying causes of these conditions, particularly immune evasion and drug resistance. Its primary focus is on creating market-disruptive biologics for recurrent and drug-resistant cancers, specifically addressing the needs of patients with recurrent metastatic breast cancer. By concentrating on these critical areas, Creative BioTherapeutics seeks to enable medical professionals to provide effective treatments for both adult and childhood cancers, potentially leading to tumor regression and improved patient outcomes.

BondTrue LLC is a medical device company focused on enhancing surgical precision through automation. The company has developed a patented device that automates the processes of surgical incisions and closures, enabling surgeons to achieve clean and consistent results while improving the accuracy of surgical procedures. This innovative technology allows for the rapid approximation and repair of surgical wounds, facilitating a more efficient workflow in the operating room. Recently, BondTrue received a Phase II award from the Maryland Industrial Partnerships program, which will support further development and research on their device. Through this funding, BondTrue aims to refine its prototype designs for subsequent research and testing, positioning itself as a key player in the advancement of surgical technologies.

Ionica Sciences, Inc. is a diagnostic company based in Ithaca, New York, founded in 2013. It specializes in developing a spectroscopy-based diagnostic platform that employs surface enhanced Raman scattering (SERS) technology. This innovative approach is designed to diagnose a range of diseases, including vector-borne, sexually transmitted, and neurological conditions. Ionica Sciences focuses on creating in-vitro diagnostic assay tests, particularly for Lyme disease and other infectious diseases, allowing medical professionals to detect biologically relevant targets such as pathogens and hormones. By providing accurate and rapid diagnostic solutions, the company aims to enhance clinical decision-making, reduce unnecessary antibiotic usage, and lower healthcare costs associated with misdiagnoses.

Claria Medical is a pre-commercial medical device start-up focused on addressing unmet needs in women's healthcare, particularly in gynecologic surgery. The company specializes in the development of minimally invasive surgical tools designed to enhance procedures such as hysterectomy and myomectomy. Claria Medical has achieved early recognition for its innovative approach, receiving a "Safer Technologies Designation" from the U.S. Food and Drug Administration. Additionally, the company has secured funding through private financing, as well as prestigious grants from the National Science Foundation and the National Institutes of Health, to support the advancement of its medical devices aimed at improving surgical outcomes for women.

FloBio is a Philadelphia-based company founded in 2017 that specializes in point-of-care diagnostics for assessing bleeding risk through real-time blood analysis. The company has developed an innovative fluidic-based diagnostic platform that leverages microfluidic technology to measure blood clotting function under physiologic conditions. This platform delivers rapid and actionable measurements, allowing clinicians to make informed decisions and personalize patient management during critical moments. By focusing on enhancing the accuracy and immediacy of blood analysis, FloBio aims to improve outcomes in medical situations where bleeding risk is a significant concern.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. It employs cell engineering techniques to create customized vesicles aimed at advancing immuno-oncology and gene therapy. By leveraging a synthetic biology approach, Jupiter Therapeutics facilitates the rapid design and synthesis of a diverse pipeline of therapeutic assets that address critical areas such as cancer and autoimmunity. The company allows medical researchers to utilize insights from cell-membrane studies to enhance the effectiveness of CAR T-cells and bi-specific antibodies, thereby contributing to innovative treatments in the biotherapeutics field.

Forcast Orthopedics is a medical technology company focused on enhancing patient outcomes following joint replacement surgery through innovative treatment methods for periprosthetic joint infections. The company has developed a proprietary automated platform that delivers targeted antibiotic therapy, modernizing the approach to infection management. By utilizing this advanced system, Forcast Orthopedics aims to provide superior patient care while also lowering costs and reducing the morbidity associated with traditional treatment methods. Through these efforts, the company seeks to significantly improve the recovery process for patients experiencing infections after joint replacement procedures.

Dascena, Inc. is a healthcare technology company based in Oakland, California, that specializes in developing machine learning algorithms aimed at enhancing disease detection and improving patient care outcomes. Established in 2018, Dascena's flagship product, AlgoDiagnostics, autonomously processes electronic health record data to facilitate early intervention for conditions such as acute decompensation, sepsis, and acute kidney injury. The company focuses on addressing unmet healthcare needs through its innovative solutions in clinical decision support, point-of-care diagnostics, and biopharma companion diagnostics. By leveraging intensive clinical research, Dascena aims to enable clinical practitioners to make timely and accurate interventions, ultimately saving lives and enhancing the delivery of care.

Inherent Biosciences is a molecular diagnostics company focused on transforming the traditional trial and error approach in medicine. The company leverages its innovative epigenetic medicine platform to address various health challenges by identifying gene dysregulation and its associated pathways. By translating biological insights into actionable information, Inherent Biosciences aims to enhance treatment strategies for conditions such as pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. This approach not only guides healthcare professionals in managing complex diseases but also seeks to provide personalized insights that empower patients in their health journeys.

Lura Health is a pioneering company that has developed a non-invasive continuous health monitoring platform utilizing saliva as a diagnostic fluid. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company focuses on chronic disease management, targeting conditions such as heart disease, chronic kidney disease, diabetes, and tooth decay. Lura Health's innovative sensors are designed to be integrated into patient-friendly orthodontic devices, including removable retainers and fixed brackets. These sensors continuously monitor oral acidity and other analytes in saliva, automatically transmitting valuable health data to a mobile application. This approach empowers users to track key diagnostic metrics within their oral environment, facilitating improved personal health management and potentially enhancing clinical outcomes.

VaxForm LLC is a consulting and contract development company specializing in vaccine formulation development. Established in 2010 and located in Nazareth, Pennsylvania, VaxForm supports clients through various stages of vaccine development, from project definition to implementation. Its services encompass pre-clinical to licensed product development for both mono- and multi-valent bacterial and viral antigens, as well as live attenuated vaccines. The company assists with formulation development activities, including antigen fermentation and purification, adjuvantation, and stabilization of vaccine products. Additionally, VaxForm provides support in creating technical reports, scientific manuscripts, and invention disclosure documents, and it reviews patent filings. This comprehensive approach enables healthcare experts to effectively advance vaccine products from conception to final drug delivery.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

Radiologics specializes in clinical research and medical imaging services, offering comprehensive software solutions designed specifically for clinical trials. The company’s platform facilitates image data management, streamlining processes such as file transfer, verification, and integration with clinical data. Additionally, it automates image processing routines and enhances connectivity, thereby assisting healthcare professionals in conducting clinical research and improving diagnostic accuracy. Radiologics’ focus on innovation in medical imaging supports advancements in clinical trials and research methodologies.

Prime Labs is a technology company that offers cloud-based SaaS platforms for mass spectrometry data processing, analysis, reporting, and visualization in the field of medical drug discovery. Its software enables scientists to conduct experiments more efficiently, accurately, and comprehensively, streamlining workflows and reducing time spent on typically tedious processes. The platform is user-friendly and requires minimal training or installation, making it accessible to a wide range of users.

Vitanova Biomedical, Inc. is an early-stage biotechnology company based in Kerrville, Texas, focused on developing innovative cancer therapies. Founded in 2015 by Matt Gdovin and Greg Espenhover, the company specializes in Light-Activated Intracellular Acidosis (LAIA), a technique that employs energy-based methods to induce cancer-specific acidosis using specific wavelengths of light and targeted nanoparticles. This approach aims to provide cost-effective and effective treatment options for cancer patients while minimizing side effects, thereby enhancing the quality of care for both patients and healthcare professionals. Vitanova Biomedical's commitment lies in delivering transformative solutions in cancer therapy.

Caza Health is a biotech company specializing in the microbiome, immunology, and oncology. The company was founded in 2019 and is headquartered in Earlysville, Virginia.

Sumaq Life is a technology company specializing in AI-driven healthcare solutions. It focuses on identifying cancer patients eligible for genomic testing by integrating with electronic medical records. The company then employs gene regulatory modeling to develop personalized treatment plans, targeting therapies with a higher likelihood of success across various aggressive cancer types, including metastatic melanoma, osteosarcoma, breast, pancreatic, lung, and colorectal cancer.

Coagulo Medical Technologies, based in Auburndale, Massachusetts, specializes in developing innovative point-of-care testing platforms for managing coagulation disorders. Their portable and connected precision-medicine system detects, identifies, and quantifies the effects of all anticoagulants in whole blood, providing healthcare providers with actionable results to improve patient outcomes.

Biocogniv Inc. is a Burlington, Vermont-based company that develops artificial intelligence-powered diagnostic tools aimed at enhancing healthcare delivery in hospitals. Founded in 2019, Biocogniv creates plugins for electronic health record systems that enable real-time screening of patients for conditions like COVID-19 by instantly analyzing standard blood test results. The company's technology focuses on improving the quality and efficiency of clinical operations by providing actionable insights derived from the vast amounts of data generated by healthcare systems. Biocogniv's platform is designed to seamlessly integrate with existing workflows in emergency departments, predicting critical outcomes such as sepsis-related in-hospital mortality and the need for intensive care unit admission. Through these innovations, Biocogniv aims to enhance the accuracy and accessibility of diagnostic methods in the medical sector.

Proteios Technology is a biotechnology company based in Issaquah, Washington, founded in 2015. It specializes in providing innovative solutions for the biopharmaceutical industry, focusing on the discovery and manufacturing of advanced therapeutics. The company has developed a flexible protein technology that supports researchers at all stages, from preclinical discovery to the production of autologous cell therapies. Proteios Technology offers a fully automated, closed system for isolating target immune cells and provides cGMP-compliant devices for efficient cell therapy manufacturing. Additionally, it supplies recombinant protein and antibody purification kits that utilize proprietary affinity tags and silica-based resins, enabling researchers to quickly and cost-effectively isolate proteins of interest.

Oscillo Biosciences is a company focused on developing innovative pharmacological treatments for Alzheimer's disease and related disorders. The firm combines a prescription medical device with digital therapeutic solutions aimed at restoring healthy brain function in individuals suffering from mild cognitive impairment and Alzheimer's disease. Their approach is rooted in the understanding that disruptions in brain rhythms affect memory and cognition in these patients. Additionally, Oscillo Biosciences creates human-centered technologies that rehabilitate patients with language, cognitive, and motor impairments by simulating the brain's synchronization to sounds and coordinating rhythmic behaviors like speech and movement. Through real-time perceptual analysis of music and various applications, their therapies offer a comprehensive method to enhance cognitive function and improve the quality of life for affected individuals.

Chosen Diagnostics is a developer of innovative biomarker diagnostic kits designed to enhance healthcare delivery for neonates. The company's primary focus is on diagnosing a prevalent and life-threatening bowel disease in preterm infants. Its diagnostic kit provides more accurate results compared to existing options, facilitating earlier medical intervention. By enabling healthcare professionals to detect critical conditions sooner, Chosen Diagnostics aims to improve treatment outcomes for thousands of low birth weight preterm infants, ultimately contributing to better health and survival rates in this vulnerable population.

Rochal Industries is a research-based company specializing in the development and manufacture of biomaterials for the wound care and eye care industries. Founded in 2014 and headquartered in San Antonio, Texas, the company produces antimicrobial materials designed to reduce opportunistic pathogens and biofilms, as well as cell-compatible substrates. Rochal Industries focuses on creating transformative products that aid in wound re-epithelialization and closure, necrotic tissue debridement, and transdermal drug delivery, guiding these products through concept development to preclinical and clinical stages while adhering to quality and regulatory standards.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally invented at Cornell University, Inso Biosciences enhances the efficiency of processing cellular material. The company's platform is designed to facilitate genomic analysis, including applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. By enabling healthcare and biotechnology companies to effectively separate and isolate cellular components, Inso Biosciences aims to transform the landscape of biological sample preparation.

AxonDx is a biotechnology company specializing in the detection of circulating tumor cells (CTCs) in blood samples, which serve as critical indicators of the presence of solid tumors and potential metastases. The company has developed the nCYTE™ technology, a device that rapidly scans un-enriched blood samples, identifying all classes of CTCs within minutes. This innovative approach not only enhances the speed and accuracy of CTC detection but also provides morphological and molecular characterization of the identified cells. By enabling earlier self-diagnosis of cancer and facilitating personalized medical treatment, AxonDx aims to transform cancer management. The company operates a "razor and blade" business model, selling nCYTE™ instruments and associated diagnostic kits for use in clinical settings, making advanced cancer detection accessible and cost-effective at the point of care.

Bioz Inc. is a technology company based in Palo Alto, California, specializing in cloud-based applications that utilize natural language processing (NLP) to aid scientific researchers. Established in 2013, Bioz operates a platform that serves as a search engine specifically for life science experimentation, allowing researchers in academia and biopharma to efficiently identify and compare reagents, instruments, and consumables for their experiments. The platform employs advanced AI to analyze data from the materials and methods sections of peer-reviewed articles, providing relevancy rankings, product ratings, and collaborative insights. By streamlining the process of finding and selecting appropriate scientific products, Bioz aims to accelerate drug discovery and enhance the success rate of finding cures for various diseases.

Opticyte, Inc. is a medical device company based in Seattle, Washington, specializing in the development of advanced algorithms and optical spectroscopy technology to monitor cellular oxygen levels. Founded in 2016 as a spinoff from the University of Washington, the company is focused on creating its first product, the Cell O2 Monitor, which aims to reduce the risk of organ failure. This innovative noninvasive oximeter measures oxygen levels within cells, enabling early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By providing clinicians with essential data, Opticyte's technology facilitates timely treatment decisions that can prevent multiple organ failure and improve patient outcomes. The company comprises teams with extensive experience in engineering, regulatory affairs, and communications, all dedicated to advancing medical device innovation.

Akanocure Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative anti-cancer therapies aimed at treating various forms of cancer, particularly those that have metastasized. Recognizing that metastasis is responsible for the majority of cancer-related deaths, Akanocure focuses on creating novel small molecules that can block metastatic processes. The company's approach emphasizes the synthesis and development of bio-targeted chemotherapeutic agents derived from natural resources, which not only target cancer cells more effectively but also address the side effects associated with conventional chemotherapy. By leveraging the expertise of its team throughout the drug discovery and development process, Akanocure aims to enhance treatment outcomes and improve the quality of life for cancer patients.

BioAmp Diagnostics, Inc. is a biotechnology company based in Berkeley, California, established in 2017. The company focuses on developing innovative diagnostic tools aimed at addressing the growing issue of antibiotic resistance. Through its patented platform amplification technology, BioAmp creates precision diagnostics that provide actionable results for medical personnel. These tests enable physicians to make informed decisions and prescribe the appropriate antibiotics for patients from the outset, thereby improving treatment outcomes and enhancing patient care. By empowering healthcare providers with critical information, BioAmp aims to facilitate the effective management of infections and contribute to the global fight against antibiotic resistance.

Viora Health is a health and wellness company focused on advancing health equity among diverse populations. It develops tech-enabled, human-centered programs that utilize social and behavioral engagement to enhance the capacity, satisfaction, outcomes, and revenue for healthcare providers. Viora Health's offerings are designed to improve adherence to diabetes prevention and support patients through online tools that track data and report progress to diabetes prevention programs, facilitating compliance with insurance requirements. Funded by reputable organizations such as the American Heart Association, the National Institutes of Health, Johnson and Johnson, and the National Science Foundation, Viora Health's initiatives have shown significant success, achieving a 75% satisfaction score and double retention rates, while also leading to improved patient outcomes such as reduced stress, increased social support, and better access to food.

Capienda Biotech is a biotechnology company focused on enhancing the drug discovery process by developing an innovative bioanalytical platform. This platform combines advanced instrumentation with assay chemistry, allowing for higher quality small molecule designs and significantly improving the efficacy of drug development. By providing crucial data that addresses a critical bottleneck in the industry, Capienda helps reduce the time and cost associated with bringing new medicines to market. Its high-throughput kinetics system offers a throughput 48 times greater than traditional methods, streamlining the process without requiring specialist scientists. The company generates recurring revenue through the sale of its laboratory instrument systems and assay chemicals, positioning itself as a key player in the biotechnology sector.

Niche Biomedical is a platform and therapy development firm that specializes in innovative treatments for chronic injuries and disorders that have not responded to conventional pharmacological methods. The company has developed the ExaStim, a non-invasive neuromodulation system designated as an FDA Breakthrough Device, aimed at treating spinal cord injuries. Additionally, Niche Biomedical is working on a gastrointestinal therapeutic device designed to alleviate postoperative ileus and restore gastrointestinal motility. This device leverages bioelectronic medicine to address diseases and injuries that are resistant to pharmaceutical therapies. The firm is also capable of creating miniaturized implantable devices with advanced functionalities, allowing for diverse electrode configurations to enhance treatment options through neuromodulation.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally invented at Cornell University, Inso Biosciences enhances the efficiency of processing cellular material. The company's platform is designed to facilitate genomic analysis, including applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. By enabling healthcare and biotechnology companies to effectively separate and isolate cellular components, Inso Biosciences aims to transform the landscape of biological sample preparation.

VivoZ Biolabs specializes in developing cell culture platforms that replicate the complex 3D tumor microenvironment. The company's flagship technology is a patented layered microfluidic tissue assay, which serves as an ex vivo platform for drug screening, diagnosis, and personalized cancer treatment. This innovative microfluidic array mimics the dynamic conditions of tumor tissue, allowing for mid-to-high throughput maintenance of micro-tumor growth and functions. This capability enables healthcare professionals to predict and select candidate compounds more effectively during the drug discovery process.